Nuvalent, Inc.
NUVL
株式のランク
#2114
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
株価
$123.96
最終同期: 2026-07-21
時価総額
$9.75B
変化（1日）
0.00%
変化（1年）
27.56%
国
US
取引 Nuvalent, Inc. (NUVL)
カテゴリー
Healthcare
Nuvalent, Inc.（NUVL）のP/B比率
October 2026 時点のP/B比率 TTM: 8.30
Nuvalent, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 8.30 です。2023 年末時点でのP/B比率は 6.12 でした。
Nuvalent, Inc. の P/B 比率の履歴（2019 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 8.30 | 70.86% |
| 2024 | 4.86 | -20.55% |
| 2023 | 6.12 | 91.44% |
| 2022 | 3.19 | 119.56% |
| 2021 | 1.46 | -98.54% |
| 2020 | 99.44 | -289.54% |
| 2019 | -52.46 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -24.72% |
US
|
|
| 13.2547 | 59.62% |
US
|
|
| 4.208 | -49.33% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -25.55% |
NL
|
